Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Hospital San Pedro de Alcántara, Cáceres

Instituto Clinico Humanitas, Milan

IRCCS Ospedale San Raffaele, Programma di Ricerca Strategica su LLC, Milan

Virginia Cancer Specialists, Gainesville

ASST Papa Giovanni XXIII Hospital Bergamo, Bergamo

Hospital Universitario de la Princesa, Madrid

Hospital Universitario Fundación Jiménez Díaz, Madrid

Hospital Universitario 12 de Octubre, Madrid

Blood & Marrow Transplant Group of GA (Northside Hospital), Atlanta

Mayo Clinic, Jacksonville

Hospital Universitario Central de Asturias, Oviedo

Mount Sinai Medical Center, Miami Beach

Moffitt Cancer Center, Tampa

Hospital Universitario de Salamanca, Salamanca

Vanderbilt University Medical Center, Nashville

Hospital Universitario Virgen del Rocio, Seville

Cleveland Clinic Foundation, Cleveland

University of Cincinnati Medical Center, Cincinnati

Hospital Universitario y Politécnico La Fe, Valencia

Henry Ford Hospital, Detroit

AOU Ospedali Riuniti Ancona, Ancona

Northwestern University, Chicago

University of Oklahoma Health Sciences Center, Oklahoma City

MD Anderson Cancer Center, Houston

University of Southern California Norris Cancer Center, Los Angeles

UCLA Department of Medicine, Los Angeles

University of California, Irvine, Irvine

Stanford Cancer Center, Stanford

UC Davis Comprehensive Cancer Center, Sacramento

Evangelismos General Hospital of Athens, Athens

Alexandra General Hospital of Athens, Athens

Istituto Europeo di Oncologia, Milan

Ospedale Santa Maria della Misericordia, Perugia

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

Amsterdam UMC, Amsterdam

UMCG Groningen, Groningen

Radboud University Medical Center, Nijmegen

Erasmus University Medical Center Rotterdam, Rotterdam

Hospital General de Albacete, Albacete

Hospital Clinic de Barcelona, Barcelona

Institut Catala d'Oncologia, Barcelona